Surgical cytoreduction for recurrent epithelial ovarian cancer
about
Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomesOvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets.Dual-color labeled anti-mucin 1 antibody for imaging of ovarian cancer: A preliminary animal studyPhthalocyanine-loaded graphene nanoplatform for imaging-guided combinatorial phototherapy.Estimating health-state utility values for patients with recurrent ovarian cancer using Functional Assessment of Cancer Therapy - General mapping algorithmsThe Lymphocyte-Monocyte Ratio Predicts Patient Survival and Aggressiveness of Ovarian CancerAssessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: a seer analysis.The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer.Feasibility of laparoscopic cytoreduction in patients with localized recurrent epithelial ovarian cancer.Targeting AMPK signaling in combating ovarian cancers: opportunities and challenges.Effects of poly (ADP-ribosyl) polymerase (PARP) inhibitor on cisplatin resistance & proliferation of the ovarian cancer C13* cellsComparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer.Current approaches and challenges in managing and monitoring treatment response in ovarian cancer.Secondary Surgery Versus Chemotherapy for Recurrent Ovarian Cancer.Hyperthermic Intraperitoneal Chemotherapy after Secondary Cytoreduction in Epithelial Ovarian Cancer: A Single-center Comparative Analysis.A Predictive Score for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer (SeC-Score): A Single-Centre, Controlled Study for Preoperative Patient Selection.Laparoscopic-based score assessment combined with a multiple disciplinary team in management of recurrent ovarian cancer: A single-center prospective study for personalized surgical therapy.Inhibitory effect of black tea pigments, theaflavin‑3/3'-gallate against cisplatin-resistant ovarian cancer cells by inducing apoptosis and G1 cell cycle arrest.Bitter Melon (Momordica charantia) Extract Inhibits Tumorigenicity and Overcomes Cisplatin-Resistance in Ovarian Cancer Cells Through Targeting AMPK Signaling Cascade.Theaflavin-3,3'-Digallate Enhances the Inhibitory Effect of Cisplatin by Regulating the Copper Transporter 1 and Glutathione in Human Ovarian Cancer Cells.Wounding promotes ovarian cancer progression and decreases efficacy of cisplatin in a syngeneic mouse model.Synergistic effect of black tea polyphenol, theaflavin-3,3'-digallate with cisplatin against cisplatin resistant human ovarian cancer cells
P2860
Q26768299-8CBB776D-F069-4AB5-A4B7-0F271E39D4DEQ34447404-93060A9E-151C-4A8F-A3BA-7AC3B7B0E96DQ35042084-41F3F500-C974-4BE9-865A-20A1901BCC64Q35229094-2F5699F9-6DF0-4621-A7C7-4EFA8043C833Q36332234-0F6482CD-AFF9-4086-A394-F428497265C1Q36563905-8BF9E5C2-C831-431B-8315-30869BEBA49FQ36575806-A93F99B4-8BE6-4444-9A56-D6D06A9775E4Q36751103-EE677CAF-3F97-449B-A43C-9AA268811AF7Q36772920-0D853FB9-8382-4940-8C9B-8D4773A64163Q36949580-A9A2FE33-0D3E-423B-8168-9359BE35EE25Q36994946-24E47DA9-7D35-4D3A-BD96-3A5D846A1A33Q37092776-A985CA73-E813-4569-AFB6-07CD45F60D3FQ37435187-5DD7BF7C-CB09-49B5-BB5F-F22FAE9499DFQ39621533-8683AFAA-F85F-4221-A761-25602F9B3D63Q40251231-1231B3E9-5888-442F-978D-0715AF7D38B6Q41161911-7A449787-9A58-423D-AB9B-BDDA981C8526Q42170049-0E938323-58AD-40A4-B0A2-B31501B81E87Q42378299-BA821B7B-0407-48D4-8F46-5A0D62C02714Q46799064-BF1FFCCE-39BB-4DC0-8AF0-9F9CF958F479Q47232215-DC87B045-44EF-4850-883F-798A6F0BCE04Q55663308-DF99CF20-771F-49C3-86F2-53AAC52EDA8CQ58570585-3513971E-252C-4557-9844-4630D421F830
P2860
Surgical cytoreduction for recurrent epithelial ovarian cancer
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Surgical cytoreduction for recurrent epithelial ovarian cancer
@ast
Surgical cytoreduction for recurrent epithelial ovarian cancer
@en
Surgical cytoreduction for recurrent epithelial ovarian cancer
@en-gb
Surgical cytoreduction for recurrent epithelial ovarian cancer
@nl
type
label
Surgical cytoreduction for recurrent epithelial ovarian cancer
@ast
Surgical cytoreduction for recurrent epithelial ovarian cancer
@en
Surgical cytoreduction for recurrent epithelial ovarian cancer
@en-gb
Surgical cytoreduction for recurrent epithelial ovarian cancer
@nl
prefLabel
Surgical cytoreduction for recurrent epithelial ovarian cancer
@ast
Surgical cytoreduction for recurrent epithelial ovarian cancer
@en
Surgical cytoreduction for recurrent epithelial ovarian cancer
@en-gb
Surgical cytoreduction for recurrent epithelial ovarian cancer
@nl
P2093
P2860
P3181
P1476
Surgical cytoreduction for recurrent epithelial ovarian cancer
@en
P2093
Ahmed Elattar
Alberto D Lopes
Andrew Bryant
Khadra Galaal
Robert E Bristow
Supratik Chattopadhyay
Thuria Al Rawahi
P2860
P304
P3181
P356
10.1002/14651858.CD008765.PUB3
P577
2013-02-28T00:00:00Z